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Previewsproliferation checkpoint genes, such as
CDKN1A, in their repressed state and,
thereby, cancer cells even tighter in their
undifferentiated phenotype. In this re-
gard, mutant EZH2 exhibits a similar
effect in GCB-DLBCL, with its hyperactiv-
ity increasing gene repression of B cell
maturation-related factors. In both aber-
ration types, a key position at the gate
toward B cell differentiation is held by
bivalent genes, whose hypermethylation
or hyper-repression with H3K27me3 fur-
ther blocks the B cells maturation pro-
cess and locks the cells in a germinal
center configuration. From a therapy
perspective, it would be of great interest
if GCB-DLBCL cases with a high degree
of epigenetic switches and hence
reduced reversibility were less sensitive
to EZH2 inhibitor treatment. Herein,
lymphoma patients with EZH2 hyper-
methylation phenotype might profit from
combinational therapies of EZH2 inhibi-
tors (McCabe et al., 2012) and DNA
demethylating agents (Herranz et al.,
2006) (Figure 1).Unlike in GCB-DLBCL, biological con-
sequences of PcTG hypermethylation
in other cancer types are not easy to
dissect. Here, PcTG silencing in cancer
types derived from tissue progenitor cells
might contribute to a transformation
process toward cancer stem cells by
effectively preventing cell differentiation.
Likewise, somatically-derived cancer
types might convert to a more undifferen-
tiated state with support of the formation
of a stem cell-like epigenetic setting.
Accordingly, in addition to DLBCL, other
tumor types might profit from therapeutic
strategies involving EZH2 inhibitors and
DNA demethylating agents.REFERENCES
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To preserve genome stability, BRCA1 must be recruited to sites of DNA damage, where BRCA1 facilitates
repair of double-strand DNA breaks (DSBs). In this issue of Cancer Cell, Li and Yu report that BRCA1 recruit-
ment involves a novel interaction between its partner protein BARD1 and poly(ADP-ribose) chains at the DSB.Germline mutations of BRCA1 are a pri-
mary cause of hereditary breast and
ovarian cancer. The central role of
BRCA1 in the cellular response to dou-
ble-strand DNA breaks (DSBs) is thought
to be a key aspect of its tumor suppres-
sion activity (Li and Greenberg, 2012).
The DSB response entails recruitment
of various signaling and repair factors,
including BRCA1, to nuclear sites of
damaged DNA. These factors selectively
accumulate at one or both of two cytolog-
ically distinct subcompartments: (1) the‘‘DSB end’’ itself and (2) the flanking
‘‘DSB chromatin’’ marked by gH2AX, a
phosphorylated form of the H2AX histone
variant (Bekker-Jensen et al., 2006). Of
note, BRCA1 can be recruited to both
subcompartments, suggesting that it
performs multiple, as yet undefined,
functions in DSB repair. Its localization
to DSB chromatin occurs through an
elaborate pathway that entails H2AX
phosphorylation, H2A polyubiquitination,
and ubiquitin-mediated recruitment of
the RAP80 complex (Li and Greenberg,2012). Ultimately, gH2AX-dependent
assembly of BRCA1 requires its direct
interaction with Abraxas, a polypeptide
within the RAP80 complex.
Early on, Celeste et al. (2003) reported
that BRCA1 recruitment to DSBs is a
kinetically biphasic process comprised
of an early gH2AX-independent stage
and a late gH2AX-dependent stage.
Subsequently, Mailand et al. (2007)
observed that BRCA1 localization to
DSB flanking chromatin, but not the DSB
end subcompartment, is ablated uponl 23, May 13, 2013 ª2013 Elsevier Inc. 565
Figure 1. Biphasic Recruitment of the BRCA1/BARD1 Tumor Suppressor to Distinct
Subcompartments of a DSB
(A) An illustration of the BRCA1/BARD1 heterodimer showing the RING and tandem BRCT motifs of both
proteins as well as the internal ankyrin repeats of BARD1. Heterodimerization of BRCA1 and BARD1 is
mediated by sequences encompassing their respective RING domains (dotted rectangle).
(B) A diagram of the chromosomal region spanning a DSB, including the ‘‘DSB end’’ subcompartment and
the flanking ‘‘DSB chromatin’’ subcompartment containing gH2AX histones. In the DNA damage
response, early recruitment of BRCA1/BARD1 to DSB ends is mediated by BARD1 BRCT recognition
of PAR (as reported here by Li and Yu, 2013), while late gH2AX-dependent recruitment to the flanking
DSB chromatin entails BRCA1 BRCT recognition of the phosphorylated Abraxas protein.
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results implied the existence of a distinct,
but unknown, mechanism for rapid
assembly of BRCA1 at DSB ends. To
elucidate this process, Li and Yu (2013;
in this issue of Cancer Cell) combined
laser microirradiation and live cell imaging
to specify the requirements for early
(<1 min post damage) and late (2–10 min
post damage) BRCA1 recruitment.
As illustrated in Figure 1, BRCA1 pos-
sesses an amino-terminal RING domain
and two carboxy-terminal BRCT repeats.
Structural studies show that two tandem
BRCT repeats can form a globular domain
that acts as a phospho-recognition
surface. Indeed, the BRCT repeats of
BRCA1 bind, in a mutually exclusive
manner, to at least three different phos-
phoproteins implicated in DSB repair,
one of which is the Abraxas polypeptide
that mediates BRCA1 assembly to DSB
chromatin (Li and Greenberg, 2012).
In vivo, BRCA1 exists as an obligate
heterodimer with BARD1, a related pro-
tein with the same configuration of RING
and BRCT motifs (Wu et al., 1996).
Although proteins that bind the BARD1
BRCT repeats have not yet been re-566 Cancer Cell 23, May 13, 2013 ª2013 Elsported, structural studies suggest that
these repeats also form a phospho-bind-
ing pocket.
Germline BARD1 mutations that
segregate with tumor susceptibility have
recently been identified in some families
with hereditary breast cancer (e.g., De
Brakeleer et al., 2010), indicating that
BARD1, like BRCA1, also serves as a tu-
mor suppressor. Indeed, most functions
of BRCA1 and BARD1, including their tu-
mor suppression activity, appear to be
mediated by the BRCA1/BARD1 hetero-
dimer (Shakya et al., 2008). Thus, Li and
Yu examined the requirements of both
proteins for BRCA1/BARD1 recruitment
to DSBs (Li and Yu, 2013). As expected,
late recruitment was dependent on the
BRCT domains of BRCA1 and abrogated
by tumor-associated mutations that
ablate its interaction with phosphorylated
Abraxas. Notably, however, early recruit-
ment of BRCA1 was independent of its
BRCT repeats, but instead required the
BRCT repeats of BARD1. Importantly,
early BRCA1 recruitment was ablated by
tumor-associated missense mutations
of BARD1, as well as artificial BARD1 mu-
tations designed to disrupt the predictedevier Inc.phospho-binding pocket of its BRCT
domain. Together, these data argue that
rapid assembly of the BRCA1/BARD1
heterodimer at DSBs is dependent on
the phospho-recognition properties of
the BARD1 BRCT domain.
A bigger surprise emerged when Li and
Yu identified the molecular factor that
mediates gH2AX-independent recruit-
ment of BRCA1/BARD1 (Li and Yu,
2013). One of the earliest steps in the
DNA damage response, occurring within
seconds of DSB formation, is recruitment
and activation of PARP1, a nuclear
enzyme that catalyzes PARylation—the
polymerization of ADP-ribosyl groups
(from donor NAD+ molecules) to form
poly(ADP-ribose) (PAR) chains and their
covalent conjugation to select substrate
proteins (Rouleau et al., 2010). Knowing
that PAR polymers are rich in phosphate
groups (two per ADP-ribosyl monomer),
Li and Yu (2013) surmised that PAR
might act as a receptor for phospho-
dependent binding by the BARD1 BRCT
domain. Through a series of stringent
analyses, they established that the
BARD1 BRCT domain does indeed
interact with PAR and does so with affin-
ities comparable to those of other known
PAR-binding motifs. Moreover, they
found that early gH2AX-independent
recruitment of BRCA1/BARD1 is ablated
upon disruption of the BARD1/PAR
interaction by various means, including
enzymatic inhibitors of PARP1 and muta-
tions that abolish the phospho-recogni-
tion properties of the BARD1 BRCT.
Tandem BRCT repeats, such as those
of BRCA1 and BARD1, are found in a
number of cellular proteins. Previously,
all the phospho-ligands reported to bind
these BRCT domains have been phos-
phorylated isoforms of proteins, such as
phospho-Abraxas. The discovery that a
nucleic acid polymer such as PAR can
functionally interact with the BARD1
BRCT domain indicates that the potential
phospho-recognition properties of BRCT
proteins may be more diverse than
anticipated. Structural studies should
uncover the molecular determinants of
the BARD1/PAR interaction and how
they relate to those that form canonical
BRCT/phosphoprotein complexes. In
addition, it will be interesting to ascertain
whether the BARD1 BRCT domain can
also bind in a traditional manner to other
as yet unknown phosphoprotein ligands,
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influenced by PAR formation.
With these new findings, a comprehen-
sive and satisfying picture has emerged to
account for the biphasic pattern of
BRCA1 assembly at DSBs (Figure 1). In
this scenario, the BRCA1/BARD1 hetero-
dimer is rapidly recruited to DSB ends in
an H2AX-independent manner by virtue
of the interaction of its BARD1 BRCT
domain with PAR. Subsequently, the het-
erodimer associates in a more durable
fashion with the flanking DSB chromatin
through the well-defined gH2AX pathway
upon interaction of its BRCA1 BRCT
domain with phosphorylated Abraxas. It
is important to note that the vast majority
of BRCA1 and BARD1 mutations asso-
ciated with hereditary breast cancer are
either (1) truncating or missense muta-
tions that ablate BRCT phospho-recogni-
tion or (2) missense mutations that
abolish BRCA1/BARD1 heterodimeri-
zation. Thus, a common denominator of
most tumor-predisposing defects is
disruption of either the early and/or late
pathways of BRCA1/BARD1 recruitment.
A key objective of future studies will be
to determine the specific functions of
BRCA1/BARD1 within each of the two
DSB subcompartments and to ascertain
whether these functions are relevant for
tumor suppression.The exquisite sensitivity of BRCA1-
and BRCA2-defective tumors to PARP
inhibitors was originally thought to
reflect a synthetic lethal effect whereby
BRCA1/2 mutant cells, which are intrinsi-
cally defective for DSB repair, are
rendered inviable by simultaneous inacti-
vation of single-strand DNA break repair,
which is normally dependent on PARP1
(Rouleau et al., 2010). However, recent
studies suggest that this model is
incomplete and that other actions of
PARP may also be relevant (Helleday,
2011). As noted by Li and Yu (2013),
most BRCA1-deficient tumors have le-
sions of the BRCA1 BRCT domains
that would disrupt the late gH2AX-
dependent, but not the early PAR-
dependent, pathway of BRCA1/BARD1
recruitment. Thus, the heightened sensi-
tivity of these cells to PARP inhibition
might reflect the fact that both modes
of BRCA1/BARD1 recruitment are abla-
ted simultaneously. As such, this work
may have important clinical implications
for the anti-cancer activity of PARP
inhibitors.ACKNOWLEDGMENTS
I am grateful to Jean Gautier for his advice and crit-
ical reading. This work was supported by grants
from the NIH.Cancer CelREFERENCES
Bekker-Jensen, S., Lukas, C., Kitagawa, R., Mel-
ander, F., Kastan, M.B., Bartek, J., and Lukas, J.
(2006). J. Cell Biol. 173, 195–206.
Celeste, A., Fernandez-Capetillo, O., Kruhlak,
M.J., Pilch, D.R., Staudt, D.W., Lee, A., Bonner,
R.F., Bonner, W.M., and Nussenzweig, A. (2003).
Nat. Cell Biol. 5, 675–679.
De Brakeleer, S., De Gre`ve, J., Loris, R., Janin, N.,
Lissens, W., Sermijn, E., and Teugels, E. (2010).
Hum. Mutat. 31, E1175–E1185.
Helleday, T. (2011). Mol. Oncol. 5, 387–393.
Li, M., and Yu, X. (2013). Cancer Cell 23, this issue,
693–704.
Li, M.L., and Greenberg, R.A. (2012). Trends
Biochem. Sci. 37, 418–424.
Mailand, N., Bekker-Jensen, S., Faustrup, H.,
Melander, F., Bartek, J., Lukas, C., and Lukas, J.
(2007). Cell 131, 887–900.
Rouleau, M., Patel, A., Hendzel, M.J., Kaufmann,
S.H., and Poirier, G.G. (2010). Nat. Rev. Cancer
10, 293–301.
Shakya, R., Szabolcs, M., McCarthy, E.E., Ospina,
E., Basso, K., Nandula, S.V., Murty, V.V., Baer, R.,
and Ludwig, T. (2008). Proc. Natl. Acad. Sci. USA
105, 7040–7045.
Wu, L.C., Wang, Z.W., Tsan, J.T., Spillman, M.A.,
Phung, A., Xu, X.L., Yang, M.-C.W., Hwang,
L.-Y., Bowcock, A.M., and Baer, R. (1996). Nat.
Genet. 14, 430–440.Chromoplexy: A New Category
of Complex Rearrangements in the Cancer GenomeMichael M. Shen1,*
1Departments of Medicine and Genetics and Development, Herbert Irving Comprehensive Cancer Center, Columbia University College of
Physicians and Surgeons, New York, NY 10032, USA
*Correspondence: mshen@columbia.edu
http://dx.doi.org/10.1016/j.ccr.2013.04.025
Widespread structural alterations of cancer genomes are increasingly observed in a broad spectrum of
tumors. In a recent issue of Cell, Baca and colleagues describe large chains of rearrangements that co-
ordinately affect multiple chromosomes in prostate cancer. This phenomenon of chromoplexy may define
cancer subtypes and drive punctuated tumor evolution.The application of next-generation
sequencing technologies has resulted in
systematic efforts to characterize the
mutational spectrum, genomic alter-ations, and clonal evolution of a wide
range of tumors. In particular, whole-
genome sequencing approaches can
reveal extensive structural rearrange-ments throughout the tumor genome,
which can be difficult to detect using
more limited exome sequencing appro-
aches. The whole-genome sequencingl 23, May 13, 2013 ª2013 Elsevier Inc. 567
